Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

Overview of attention for article published in Frontiers in Neurology, May 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 48 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 70 publications that cite this research output.

70

The most recent citing publications are shown below. View all 70 publications that cite this research output on Dimensions.

Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications

Article in Frontiers in Neurology (June 2024)

Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis

Article in European Journal of Pharmacology (May 2024)

MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment

Article in The Journal of Headache and Pain (May 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.